Scientific Reports · 2016 · 22 citations · 19 references
MedicineOncologyEndocrine OncologyImmunotherapyTumor ProgressionAntithyroid DrugsTyrosine Kinase InhibitorsPartial Response AssessmentProgressive Disease AssessmentRecist CriteriaRefractory Thyroid CarcinomaTumor Marker KineticsTumor Progression DynamicsTumor Progression MonitoringTumor Restaging By Imaging
Tyrosine kinase inhibitors (TKI) have shown clinical effectiveness in iodine-refractory differentiated thyroid cancer (DTC). The corresponding role of serum thyroglobulin (Tg) in iodine-refractory DTC has not been investigated yet. 9 patients (3 female, 61 ± 8y) with progressive iodine-refractory DTC starting on lenvatinib were considered. Tumor restaging was performed every 2-3 months including contrast-enhanced computed tomography (CT, RECIST 1.1). Serum Tg was measured and compared to imaging findings. After treatment initiation, serum Tg levels dropped in all patients with a median reduction of 86.2%. During long-term follow-up (median, 25.2 months), fluctuations in Tg could be observed in 8/9 subjects. According to RECIST, 6/9 subjects achieved a partial response or stable disease with the remaining 3/9 experiencing progressive disease (2/3 with Tg levels rising above baseline). All of the patients with disease progression presented with a preceding continuous rise in serum Tg, whereas tumor marker oscillations in the subjects with controlled disease were only intermittent. Initiation of lenvatinib in iodine-refractory DTC patients is associated with a significant reduction in serum Tg levels as a marker of treatment response. In the course of treatment, transient Tg oscillations are a frequent phenomenon that may not necessarily reflect morphologic tumor progression.
19
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Martin Schlumberger, Makoto Tahara, Lori J. Wirth et al. · New England Journal of Medicine · 2015 · 2.1K citations · Full text
Cosimo Durante, Nadia Haddy, E. Baudin et al. · The Journal of Clinical Endocrinology & Metabolism · 2006 · 1.7K citations
Ahmedin Jemal, Edgar P. Simard, Christina Dorell et al. · JNCI Journal of the National Cancer Institute · 2013 · 997 citations · Full text